• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Merck Serono - Articles and news items

osteoarthritis

‘Seismic changes’ coming to the osteoarthritis treatment market

Industry news / 24 February 2016 / Victoria White

The osteoarthritis treatment market will experience seismic changes over the next decade, according to a GlobalData analyst…

ATX-MS-1467

Enrolment completes for Phase IIa trial of ATX-MS-1467

Industry news / 6 August 2015 / Victoria White

Apitope today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736)…

gfi

Merck Serono commits € 1.2 million to the Grant for Fertility Innovation (GFI) for 2015 / 16

Industry news / 18 June 2015 / Victoria White

Merck Serono has announced its strong support of the Grant for Fertility Innovation (GFI) fund with grants totalling up to € 1.2 million for 2015 / 2016…

red-dot

Merck Serono wins two Red Dot Awards for its fertility pens

Industry news / 11 June 2015 / Victoria White

Merck Serono has announced that the product design of its fertility pens won over the 38-member jury of the Red Dot Award: Product Design 2015…

ICR

Merck Serono to collaborate with The Institute of Cancer Research, London, and Wellcome Trust to co-develop anti-cancer drugs

Industry news / 8 October 2014 / The Wellcome Trust, The Institute of Cancer Research & Merck Serono

Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family…

Merck KGaA and Lead Discovery Center Enter Collaboration for the Discovery of Anti-Cancer Compounds

Industry news, News / 20 January 2011 / Merck Serono

Merck Serono, announced today that Merck KGaA has signed a cooperation agreement with the Lead Discovery Center GmbH (LDC)…

Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOX

Industry news, News / 19 January 2011 / Merck KGaA

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUSa study…

Domain Therapeutics and Merck Serono announce an agreement to develop drugs for Parkinson’s disease

Industry news, News / 17 January 2011 / Andrew Lloyd & Associates

Agreement covers metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +